What a buyer sees
SMARTWAY PHARMACEUTICALS LIMITED
Wholesale of pharmaceutical goods · Leicester · 08481191
97staff · FY2023
13years trading
—oldest owner on file
£3.8Mcash at bank
Your turnover is on public record
filed£146Mfor the year to 2023
Unusual at this size, and it works in your favour: a buyer is reading your number rather than guessing at one.
What your filings show moving
Staff97
202186 → 972023
Cash at bank£3.8M
2021£5.5M → £3.8M2023
How you sit in your trade
slowest tenth typical fastest tenth youSales per employee£1,507,178in the top quarter
£185,740£589,651£1,764,935
Debtor daysdays96in the middle half
3460147
Creditor daysdays14
931101
Stock daysdays46in the middle half
1950109
Each spread is companies in the same trade and size that did publish a turnover. Creditor days are shown but not marked: neither end of that one is plainly good.
What a buyer would ask 3
- The newest accounts on file are 41 months oldAnyone looking at the company today is reading a year that has already ended. Whatever has improved since is invisible.
- A director resigned in the past yearA buyer will ask why, and will hear the answer from somewhere. Better from you.
- No website on file against the companyThe first thing anyone does with a company number is look for the business behind it. Finding nothing is its own answer.
What a buyer would like 2
- Headcount grew from 81 to 97Growth a buyer can verify without asking you for anything.
- Sales per employee better than three quarters of your tradeYours is 1,507,178 against 589,651 for the middle of 74 comparable companies.
What the register says
Owners
Nobody recorded with significant control.
Directors
- 42since 2022
- 36since 2025
| Year to | Turnover | Staff | Cash |
|---|---|---|---|
| 2023-03-31 | £146M | 97 | £3.8M |
| 2022-03-31 | £135M | 81 | £8.3M |
| 2021-03-31 | £196M | 86 | £5.5M |
A rough bracket, and why it is only that
0.35–0.55× sales£51M£80M
The turnover range is fitted on UK companies that did file one. The multiple is a published sector average from Dutch mid-market deals, not from your own numbers and not from your own market. Treat this as the opening bracket of a conversation, not a valuation.